OTTMUSG00000019138 Inhibitors

Sorafenib, a kinase inhibitor, targets multiple kinases like VEGFR and PDGFR which are involved in angiogenesis and cell proliferation. By inhibiting these kinases, Sorafenib disrupts the signaling pathways crucial for tumor cell proliferation and angiogenesis, thereby inhibiting the growth of cancer cells expressing ovary testis transcribed olfactory receptor family 52 subfamily E member 19.

Dasatinib is a potent inhibitor of multiple tyrosine kinases including BCR-ABL and Src family kinases. By inhibiting Src kinases, Dasatinib affects cellular processes like cell growth and survival that are vital for the function of ovary testis transcribed olfactory receptor family 52 subfamily E member 19 in cancer cells, leading to their inhibition.

Erlotinib is an EGFR inhibitor, specifically targeting the epidermal growth factor receptor tyrosine kinase. By blocking EGFR, Erlotinib disrupts important signaling pathways that contribute to the proliferation and survival of cells expressing ovary testis transcribed olfactory receptor family 52 subfamily E member 19, thereby inhibiting these cells.

Imatinib is a selective tyrosine kinase inhibitor, particularly targeting BCR-ABL, c-Kit, and PDGF receptors. It blocks the kinase activity of these proteins, thus inhibiting signaling pathways critical for cancer cell growth and survival where ovary testis transcribed olfactory receptor family 52 subfamily E member 19 is expressed.

Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor, affecting receptors like VEGFR and PDGFR. It impedes angiogenesis and cell proliferation pathways, leading to the inhibition of cells expressing ovary testis transcribed olfactory receptor family 52 subfamily E member 19.

Lapatinib, a dual tyrosine kinase inhibitor, targets both EGFR and HER2/neu. Inhibition of these receptors interrupts signaling pathways essential for the survival and proliferation of cells expressing ovary testis transcribed olfactory receptor family 52 subfamily E member 19.

Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor. It blocks this kinase, thereby disrupting downstream signaling pathways involved in the proliferation and survival of cancer cells where ovary testis transcribed olfactory receptor family 52 subfamily E member 19 is expressed.

Pazopanib is a multi-targeted receptor tyrosine kinase inhibitor, affecting VEGFR, PDGFR, and c-Kit. By inhibiting these kinases, Pazopanib disrupts angiogenesis and cell proliferation, thus hindering the function of cells expressing ovary testis transcribed olfactory receptor family 52 subfamily E member 19.

Vandetanib selectively inhibits VEGFR, EGFR, and RET-tyrosine kinases. By blocking these kinases, Vandetanib interferes with crucial signaling pathways, leading to the inhibition of cancer cells expressing ovary testis transcribed olfactory receptor family 52 subfamily E member 19.

Afatinib-d4 is an irreversible inhibitor of EGFR and HER2. By covalently binding to these receptors, Afatinib disrupts key signaling pathways, leading to the inhibition of cells expressing ovary testis transcribed olfactory receptor family 52 subfamily E member 19.